- Home
- SA vs ELVN Comparison
SA vs ELVN Comparison
Compare SA & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SA | ELVN |
|---|---|---|
| Founded | 1979 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 1.8B |
| IPO Year | 2004 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SA | ELVN |
|---|---|---|
| Price | $24.34 | $28.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $65.00 | $41.00 |
| AVG Volume (30 Days) | ★ 897.2K | 752.0K |
| Earning Date | 04-06-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.40 | $13.30 |
| 52 Week High | $40.06 | $31.76 |
Technical Indicators
Market Signals| Indicator | SA | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 25.92 | 52.42 |
| Support Level | $21.84 | $19.10 |
| Resistance Level | $31.26 | $29.63 |
| Average True Range (ATR) | 1.87 | 1.87 |
| MACD | -1.31 | -0.23 |
| Stochastic Oscillator | 5.63 | 39.76 |
Price Performance
Historical ComparisonAbout SA Seabridge Gold Inc. (Canada)
Seabridge Gold Inc is a development stage company involved in the exploration, and development of gold properties sited in North America. The company's principal projects include the Kerr-Sulphurets-Mitchell property located in British Columbia, the Courageous Lake property located in the Northwest Territories, and Iksut Property located in northwestern British Columbia, and the 3 Aces Project in southeast Yukon. The company has various other mineral resource projects throughout North America.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.